

AI contd  
24. A vaccine composition according to claim 23 in which the preferential stimulator of TH1-cell response is 3D-MPL.

25. A vaccine composition according to claim 21 in which the HSV antigen is HSV-2 gD or a truncate thereof.

26. A vaccine composition according to claim 21 which comprises at least one HPV antigen selected from the group consisting of L1, L2, E6 and E7, optionally in the form of a fusion protein and/or a truncate.

27. A vaccine composition according to claim 21 in which an EBV antigen is additionally present.

28. A vaccine composition as defined in claim 27 in which the EBV antigen is gp 350.

29. A vaccine composition according to claim 21 in which a hepatitis A antigen is additionally present.

30. A vaccine composition according to claim 27 in which a hepatitis A antigen is additionally present.

31. A vaccine composition according to claim 29 in which the HAV antigen is derived from the HM-175 strain.

32. A vaccine composition according to claim 30 in which the HAV antigen is derived from the HM-175 strain.

33. A vaccine composition according to claim 21 in which a hepatitis B virus (HBV) antigen is additionally present.

Int'l. Appln. No.: PCT/EP00/08784  
Docket No. B45198

34. A vaccine composition according to claim 27 in which a hepatitis B virus (HBV) antigen is additionally present.

AI  
cont'd 35. A vaccine composition according to claim 29 in which a hepatitis B virus (HBV) antigen is additionally present.

36. A vaccine composition according to claim 33 in which the HBV antigen is hepatitis B surface antigen.

37. A vaccine composition according to claim 27 in which the HBV antigen is hepatitis B surface antigen.

38. A vaccine composition according to claim 29 in which the HBV antigen is hepatitis B surface antigen.

39. A vaccine composition according to claim 21 in which the carrier is selected from the group comprising aluminium hydroxide, aluminium phosphate and tocopherol and an oil in water emulsion.

40. A vaccine composition according to claim 21 which additionally comprises a VZV antigen.


41. A vaccine composition according to claim 27 which additionally comprises a VZV antigen.

42. A vaccine composition according to claim 29 which additionally comprises a VZV antigen.

43. A vaccine composition according to claim 33 which additionally comprises a VZV antigen.

44. A vaccine composition according to claim 40 in which the VZV antigen is gpl.

- AI  
cont'd
45. A vaccine composition according to claim 41 in which the VZV antigen is gpI.
  46. A vaccine composition according to claim 42 in which the VZV antigen is gpI.
  47. A vaccine composition according to claim 43 in which the VZV antigen is gpI.
  48. A vaccine composition according to claim 21 which additionally comprises a HCMV antigen.
  49. A vaccine composition according to claim 27 which additionally comprises a HCMV antigen.
  50. A vaccine composition according to claim 29 which additionally comprises a HCMV antigen.
  51. A vaccine composition according to claim 33 which additionally comprises a HCMV antigen.
  52. A vaccine composition according to claim 40 which additionally comprises a HCMV antigen.
  53. A vaccine composition according to claim 48 in which the HCMV antigen is gB685\*\* or pp65.
  54. A vaccine composition according to claim 49 in which the HCMV antigen is gB685\*\* or pp65.
  55. A vaccine composition according to claim 50 in which the HCMV antigen is gB685\*\* or pp65.



Int'l. Appln. No.: PCT/EP06/08784  
Docket No. B45198

56. A vaccine composition according to claim 51 in which the HCMV antigen is gB685\*\* or pp65.

57. A vaccine composition according to claim 52 in which the HCMV antigen is gB685\*\* or pp65.

58. A vaccine composition according to claim 21 which additionally comprises a *Toxoplasma gondii* antigen.

59. A vaccine composition according to claim 27 which additionally comprises a *Toxoplasma gondii* antigen.

60. A vaccine composition according to claim 29 which additionally comprises a *Toxoplasma gondii* antigen.

61. A vaccine composition according to claim 33 which additionally comprises a *Toxoplasma gondii* antigen.

62. A vaccine composition according to claim 40 which additionally comprises a *Toxoplasma gondii* antigen.

63. A vaccine composition according to claim 48 which additionally comprises a *Toxoplasma gondii* antigen.

64. A vaccine composition according to claim 57 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

65. A vaccine composition according to claim 59 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.

66. A vaccine composition according to claim 60 in which the *Toxoplasma gondii* antigen is SAG1 or TG34.